New partnerships with national Complex Rehab Technology (CRT) and prosthetics/orthotics providers are expected to grow Ekso Bionics’ Personal Health Products segment for 2025, the company announced during its May 5 earnings call.
Ekso Bionics (Nasdaq: EKSO) reported earnings results for the three months ending on March 31, 2025, while also commenting on what the company is anticipating for the rest of the year.
In February, Ekso Bionics announced it had signed an agreement for National Seating & Mobility (NSM) to be the exclusive distributor of the Ekso Indego Personal exoskeleton within the CRT industry. In April, Ekso Bionics announced an agreement with Bionics Prosthetics & Orthotics Group (Bionics P&O) as a non-exclusive Indego Personal distributor.
The Ekso Indego Personal is a wearable lower-extremity exoskeleton that can enable “many individuals living with spinal cord injuries (SCI) the ability to stand and walk independently,” NSM said in its announcement about the Ekso Bionics partnership.
The company described the Indego Personal exoskeleton as having “a modular quick-connect design, which was engineered to allow users to put on and take off the device without assistance.” The exoskeleton also has “an advanced gait mode” that can enable users using the device “to reach faster walking speeds, granting them a new level of independence in the community.”
“Over the past few weeks, we have significantly expanded access to Ekso Indego Personal via potentially transformative partnerships with two key leaders within their respective industries,” said Scott Davis, Ekso Bionics’ CEO, during the earnings call. “NSM, which operates in the CRT industry, brings a network of over 180 locations and more than 2,400 team members, who support more than 250,000 mobility solutions each year. Bionic P&O, a leading national provider of prosthetic and orthotic solutions, is an ABC-accredited, independent clinical practice group that now operates across 12 states.
“Both partnerships represent Ekso Bionics’ first entrances into these large and growing markets, and we believe that will start to see increased contribution from our Personal Health products in 2025 as a result.”
Ekso Bionics, headquartered in San Rafael, California, reported first-quarter 2025 revenue of $3.4 million, compared to $3.8 million for the first quarter of 2024. “The change was primarily due to lower sales of legacy EksoNR devices, partially offset by higher Ekso Indego Personal device sales,” the company said in a press release of its earnings call.
